Capricor Therapeutics, Inc. (NASDAQ:CAPR) reported insider activity this week as director Sabar Karimah Es sold a total of 115,000 shares of the company's common stock in two separate transactions that aggregated to roughly $3.5 million. The share disposals followed the exercise of options by Es to acquire the same number of shares at a substantially lower strike price.
The stock has been trading at $30.06, representing a gain of more than 209% over the last 12 months, according to InvestingPro data. The trades were carried out under a prearranged 10b5-1 trading plan that the director adopted in December 2025.
On March 31, 2026, Es sold 61,265 shares at a weighted average price of $30.168 per share, with execution prices spanning from $30.00 to $30.46. The following day, April 1, 2026, she sold the remaining 53,735 shares at a weighted average price of $31.0268, with prices in those trades ranging from $30.28 to $31.39.
Concurrent with the sales, Es exercised options to obtain 115,000 shares of Capricor common stock at an exercise price of $4.86 per share, for a total outlay of $558,900. Those option exercises occurred on March 31 and April 1, 2026.
InvestingPro's analysis, as noted in company reporting, indicates the stock may still be undervalued, with additional commentary and detailed evaluation available through the platform’s Pro Research Report.
On the corporate results front, Capricor disclosed fourth-quarter fiscal 2025 earnings that showed a wider-than-expected loss. The company posted earnings per share of -0.62, missing analyst estimates of -0.51 and producing a negative surprise of 21.57%.
Despite the earnings miss, Cantor Fitzgerald reiterated an Overweight rating on Capricor and kept a price target of $62.00. The firm’s continued positive stance appears tied to the company’s strategic initiatives and clinical progress.
Capricor highlighted several near-term development milestones, including a PDUFA date set for August 22, 2026 for deramiocel, a cardiosphere-derived cell therapy being developed for Duchenne muscular dystrophy. The company also presented new HOPE-3 data at the Muscular Dystrophy Association meeting, underscoring ongoing clinical activity focused on advancing the therapeutic pipeline.
These transactions and corporate updates provide a snapshot of insider liquidity, capital deployment via option exercise, and recent operating results as Capricor progresses through regulatory and clinical milestones.